Patients who underwent neoadjuvant chemotherapy (NACT) were significantly younger and more likely to be premenopausal and having a triple negative or HER2 positive breast cancer than patients who underwent upfront surgery (Table 1). The gene discussed is ERBB2; the disease is breast cancer.